Supplementary Table S3 from Botensilimab, an Fc-Enhanced Anti–CTLA-4 Antibody, Is Effective against Tumors Poorly Responsive to Conventional Immunotherapy
Authors:
- Dhan ChandDCDhan Chand
- David A. SavitskyDSDavid A. Savitsky
- Shanmugarajan KrishnanSKShanmugarajan Krishnan
- Gabriel MednickGMGabriel Mednick
- Chloe DelepineCDChloe Delepine
- Pilar Garcia-BroncanoPGPilar Garcia-Broncano
- Kah Teong SohKSKah Teong Soh
- Wei WuWWWei Wu
- Margaret K. WilkensMWMargaret K. Wilkens
- Olga UdartsevaOUOlga Udartseva
- Sylvia VincentSVSylvia Vincent
- Bishnu JoshiBJBishnu Joshi
Open Access
- 17 June 2026
- other
- Published by American Association for Cancer Research (AACR)